Hongene is thrilled to announce our participation in 5th Annual Oligonucleotides CMC & Analytical Development Summit.
Scaling DNA & Large RNA Construct Production, Analytics, & Quality Control for cGMP Compliant Vaccines, Therapeutics, & RNA-Based Cell & Gene Therapies
As oligonucleotide therapeutics continue to advance across ASOs, siRNA, gRNA, and increasingly complex conjugates, analytical development, process development, quality control and CMC teams face growing pressure to deliver robust, scalable and regulatory-ready programs.
From oligonucleotide characterization, impurity profiling, LC-MS analytics, control strategy development, and comparability assessments through to GMP manufacturing, organizations must align analytical and CMC strategies with increasing FDA and global regulatory expectations.
Returning to Boston, the 5th Oligonucleotide Analytical Development & CMC Summit brings together 90+ leaders spanning Analytical Development, CMC, Process Development, Quality Control, Analytical Science, Regulatory Affairs, and Manufacturing to share practical case studies and establish best practices for bringing high-quality oligonucleotide therapeutics to market.
Welcome to visit us at site, booth No. #1. Let’s discuss how Hongene’s high-quality nucleic acid products and end-to-end RNA medicines solution can help make your project successful.